KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Liabilities (2020 - 2025)

AbCellera Biologics' Total Liabilities history spans 6 years, with the latest figure at $392.0 million for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities rose 24.54% year-over-year to $392.0 million, compared with a TTM value of $392.0 million through Sep 2025, up 24.54%, and an annual FY2024 reading of $304.5 million, down 9.32% over the prior year.
  • Total Liabilities for Q3 2025 was $392.0 million at AbCellera Biologics, down from $395.0 million in the prior quarter.
  • The five-year high for Total Liabilities was $395.0 million in Q2 2025, with the low at $171.4 million in Q1 2021.
  • Average Total Liabilities over 5 years is $310.6 million, with a median of $314.7 million recorded in 2024.
  • Year-over-year, Total Liabilities surged 345.74% in 2021 and then fell 24.78% in 2023.
  • Tracing ABCL's Total Liabilities over 5 years: stood at $292.8 million in 2021, then increased by 5.05% to $307.6 million in 2022, then grew by 9.15% to $335.8 million in 2023, then dropped by 9.32% to $304.5 million in 2024, then increased by 28.73% to $392.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Total Liabilities are $392.0 million (Q3 2025), $395.0 million (Q2 2025), and $321.2 million (Q1 2025).